Medpace Stock (NASDAQ:MEDP)
Previous Close
$305.00
52W Range
$272.00 - $459.77
50D Avg
$323.31
200D Avg
$348.79
Market Cap
$9.03B
Avg Vol (3M)
$417.56K
Beta
1.46
Div Yield
-
MEDP Company Profile
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
MEDP Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 24 | Dec 22 | Dec 21 |
|---|---|---|---|
| Antiviral And Anti Infective | $156.46M | $118.03M | $110.98M |
| Cardiology | $230.45M | $174.63M | $119.69M |
| Central Nervous System | $181.98M | $157.94M | $121.55M |
| Metabolic | $457.54M | $244.68M | $159.90M |
| Oncology | $651.24M | $467.80M | $362.85M |
| Other | $431.38M | $296.91M | $267.42M |
| Revenue Net | - | $1.46B | $34.50M |
Fiscal year ends in Dec 24 | Currency in USD
Peer Comparison
| Ticker | Company |
|---|---|
| TWST | Twist Bioscience Corporation |
| WAT | Waters Corporation |
| MTD | Mettler-Toledo International Inc. |
| ICLR | ICON Public Limited Company |
| NEOG | Neogen Corporation |
| IQV | IQVIA Holdings Inc. |
| QGEN | Qiagen N.V. |
| RVTY | Revvity, Inc. |
| IDXX | IDEXX Laboratories, Inc. |
| LH | Laboratory Corporation of America Holdings |
| CRL | Charles River Laboratories International, Inc. |